Medtech and life science tools economics

Industrials wearing a healthcare label

If biopharma is the sub-sector where standard valuation tools break down, medtech and life science tools are close to the opposite case: once a product has real market traction, its economics look a great deal like a well-run industrials or consumer-durables business, and the standard toolkit, DCF, EV/EBITDA, EV/Revenue, works about as well here as it does anywhere else in banking. That doesn't make the sub-sector simple. It makes it a different kind of complicated, built around adoption curves, recurring consumables, reimbursement, and switching costs rather than clinical trial risk.

Understanding this sub-sector well is also the fastest way to demonstrate range in a healthcare interview, because it's the clearest contrast to biopharma valuation covered in how biotech companies are valued. Interviewers love asking a candidate to explain why two companies inside the same "healthcare" umbrella get valued so differently, and medtech versus biopharma is the cleanest possible pair to use in an answer.

The razor-and-blade model

A large share of the medtech sub-sector runs on a model borrowed straight from consumer products: sell the durable capital equipment once, often at a thin margin or even close to cost, and then sell the disposable consumables that piece of equipment requires for every subsequent use, at a much higher margin, for as long as the equipment stays in service. A hospital might buy a piece of surgical or diagnostic equipment as a one-time capital purchase, but every procedure performed on that equipment afterward requires a new disposable component, and that stream of consumable sales is what actually drives the device maker's long-term, recurring revenue.

This model matters for valuation because it means a medtech company's installed base, the number of pieces of its equipment actually in use across hospitals and clinics, is often a more important number than its current-year equipment sales. A company that has placed a large installed base in prior years, even if new equipment sales slow down in any given year, still earns a steady, predictable consumables stream from every unit already out in the field. Interviewers sometimes test this directly by asking a candidate to explain why a medtech company's revenue could keep growing even if unit sales of the underlying equipment flatten, and the installed-base-driven consumables stream is exactly the answer.

Reimbursement, adoption, and why a great product can still stall

A device doesn't sell itself just by being clinically superior. For most of the sub-sector, a new device only gets adopted at scale once a payor agrees to reimburse the procedure that uses it, which means a device company's growth trajectory is gated by a process largely outside its own control. A brand-new device with genuinely better clinical outcomes than the existing standard of care can still see slow initial adoption if payors haven't yet established, or haven't yet agreed to, reimbursement for the procedure at a rate that makes it economically attractive for a hospital or physician to use it over the older, already-reimbursed alternative.

This is the same reimbursement dynamic that drives providers and payors, covered fully in healthcare services: providers and payors, showing up from a different angle: instead of a hospital's own revenue depending on reimbursement, a device maker's adoption curve depends on it. A healthcare banker evaluating a medtech company's growth prospects has to ask not just "is this a better product" but "will the people who'd have to pay for it actually get paid enough to want to switch."

Switching costs and clinician preference

Once a device is adopted, it tends to stay adopted for longer than a comparable consumer product would, because clinical switching costs run higher than most switching costs elsewhere in the economy. A surgeon trained on a particular device, comfortable with its specific handling and performance characteristics, has a real incentive to keep using it even when a competitor introduces something new, because retraining carries both time cost and a period of reduced comfort that could affect patient outcomes. A hospital that has negotiated a contract and trained its staff around a given system faces its own switching costs on top of that. This combination, physician preference plus institutional contracting, is a meaningful competitive moat in medtech, and it's part of why an established device maker with a large installed base can often defend its position even against a technically superior new entrant for a meaningful stretch of time.

Life science tools: picks and shovels for biopharma research

Life science tools companies sell a different kind of product to a different kind of customer: instruments, reagents, and lab consumables sold to biopharma companies, contract research organizations, and academic labs conducting research and drug development, rather than to hospitals treating patients. This makes the sub-sector a genuine picks-and-shovels play on the broader biopharma industry, since a tools company's revenue depends on the overall volume of research being conducted across its customer base rather than on any single drug's success.

That indirection is actually a source of relative stability compared to biopharma itself. A tools company doesn't need any particular drug candidate to succeed in order to keep growing, because its customers keep running experiments and buying reagents and instruments regardless of whether any one specific program in their pipeline ultimately works out. The tradeoff is that a tools company's growth is tied to the overall level of research spending across its customer base, which means it can slow when biopharma funding conditions tighten broadly, even if no single customer relationship has changed. A tools company's revenue mix looks similar to medtech's in structure, instruments sold once, reagents and consumables sold repeatedly, which is why the two sub-sectors are often analyzed together and valued with similar multiples-based approaches.

Diagnostics: testing that still needs reimbursement to scale

Diagnostics companies sell tests used to detect, monitor, or characterize disease, and they sit at an interesting intersection of the dynamics already described. Like medtech, a diagnostic test needs physician and clinical adoption to reach scale. Like providers, a diagnostic company's growth is gated by reimbursement, since a test that a payor won't cover struggles to get ordered routinely regardless of how clinically useful it is, because patients and providers are reluctant to absorb an uncovered cost themselves. A diagnostics company developing a genuinely novel test category, one that doesn't fit neatly into an existing reimbursement code, faces a real and sometimes lengthy challenge in getting payors to establish appropriate coverage and payment, which is a distinct commercial risk on top of the underlying clinical and regulatory risk of getting the test approved in the first place.

Consolidation and tuck-in acquisitions

Both medtech and life science tools are sub-sectors with a long history of consolidation, and it's worth understanding why, since it's a recurring theme in interviews about deal rationale. A large medtech or tools company with an established sales force and distribution network can often generate far more revenue from a smaller company's product than the smaller company could on its own, simply by pushing that product through a much larger existing customer base of hospitals or labs. That makes smaller, innovative device and tools companies attractive tuck-in acquisition targets: the strategic buyer isn't just paying for the product itself, it's paying for the ability to distribute that product at a scale the seller could never reach independently.

This differs in an important way from the pipeline-driven M&A logic in biopharma. A pharma company usually acquires a biotech to replace revenue it knows is about to decline from an expiring patent, a defensive and time-pressured rationale. A medtech or tools acquirer is more often making an offensive bet: the target's technology is sound and already selling, and the acquirer believes its own commercial engine can grow that revenue faster than the target could alone. Both rationales show up as "why did this deal happen" questions, and being able to name which logic applies to which sub-sector is a useful distinction to have ready.

Why conventional multiples actually work here

The reason this whole sub-sector can be valued with EV/EBITDA and EV/Revenue, unlike pre-revenue biopharma, comes down to one structural fact: once a device, instrument, or test has meaningful market adoption, it generates real, recurring, largely predictable cash flow, the same kind of cash flow a normal industrials or consumer-durables business generates. There's no binary "does this ever generate revenue at all" question hanging over a commercial-stage medtech or tools company the way there is over a clinical-stage drug candidate. The valuation questions that remain, how durable is the installed base, how exposed is the growth rate to a reimbursement policy change, how strong are the switching costs protecting market share, are real and substantive, but they're the same category of question an analyst would ask about any industrials business with a recurring-revenue component, not a fundamentally different kind of uncertainty.

This is exactly the contrast worth having ready in an interview: biopharma requires an entirely different valuation framework because its core uncertainty is binary and unresolved, while medtech and tools use the conventional toolkit because their core uncertainty, once a product reaches the market, is about growth durability rather than whether any cash flow exists at all. Being able to draw that line clearly is a strong signal that you understand the sector rather than having memorized a single valuation method and applied it everywhere, a mismatch covered directly in pitching a healthcare stock.

Practice question

Why can a medtech company be valued with a normal EV/EBITDA multiple while a clinical-stage biotech can't?

It comes down to whether the core uncertainty is about whether any cash flow exists at all, or about how fast existing cash flow will grow. A clinical-stage biotech has no approved product, so there's a real, binary chance its entire pipeline never generates revenue, which is why the sector uses a risk-adjusted valuation that explicitly prices the probability of ever reaching the market. A commercial-stage medtech company, once its device has real adoption, already has a working, revenue-generating business, often built on a razor-and-blade model where the device itself is sold once and higher-margin disposable consumables get sold repeatedly for every subsequent use. Its remaining uncertainty is about growth durability: how big the installed base can get, whether reimbursement policy stays favorable for the procedures using its device, and how strong its switching costs are against new entrants. Those are the same kinds of questions you'd ask about a normal industrials business with recurring revenue, which is exactly why a conventional multiple, EV/EBITDA or EV/Revenue, works fine here even though it fails completely for a pre-revenue biotech a few rows away on the same coverage list.

What the interviewer is listening for: a clear, mechanism-based explanation of the binary-versus-growth distinction, not just a restatement that "biotech is riskier." Bonus points for naming the installed-base and reimbursement dynamics specific to medtech rather than leaving the medtech side of the comparison vague.